Hoag selected as trial site for first person to receive novel COVID-19 vaccine candidate

On Wednesday, Oct. 21, an individual at Hoag Hospital Newport Beach became the first person to be dosed in the Phase 1 clinical trial of hAd5-COVID-19. The novel COVID-19 vaccine candidate targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

The Phase 1 trial, under development in a collaboration between NantKwest, Inc. and ImmunityBio, selected Hoag as the trial site and is enrolling 35 healthy adults ages 18 to 55 years old with the goal of examining the safety, side effects and immune system’s response of two successive doses of the vaccine candidate.

Hoag selected Robinson, Cao, Heim

Click on photo for a larger image

Photos courtesy of Hoag Hospital

(L-R) Philip Robinson, M.D., FIDSA, Hoag medical director of infection prevention and hospital epidemiology with Chen Cao, the first person to receive novel COVID-19 vaccine candidate in Phase 1 clinical trial with Laura Heim, RN, clinical research nurse administering the vaccine

With a reputation for providing world-class care, Hoag was selected as the trial site based on its comprehensive center for research and education that annually conducts more than 150 translational clinical trials funded by government, philanthropic foundations and industry sponsors, as well as its collaborative culture of innovation focusing on evidence-based best practices, expert medical staff and extensive clinical research infrastructure.

Since March, Hoag has participated in more than 20 COVID-19 clinical trials, providing patient access to cutting-edge therapies and innovative treatment including options that have documented improved outcomes, including decreased mortality and decreased length of stay for hospitalized COVID-19 patients. 

“We are privileged to be a part of this groundbreaking clinical trial with NantKwest and ImmunityBio,” said Dr. Philip Robinson, medical director of infection prevention at Hoag and principal investigator (PI) of the vaccine trial. “Since caring for the state’s first known COVID-19 patient back in January, Hoag has been working tirelessly on the frontlines of this rapidly evolving pandemic to care for all of our patients and give them access to the latest advancements in treatment options.”

Hoag selected Pharmacy technician

Click on photo for a larger image

Pharmacy technician measures dose for COVID-19 vaccine clinical trial

This is the first COVID vaccine trial conducted at Hoag and the first trial of this novel vaccine conducted anywhere in the United States.

“Our vaccine candidate, hdA5-COVID-19, is one of the only vaccine candidates in development that targets both the nucleocapsid protein on the interior of the virus particle and the spike protein on the virus’ surface,” said Dr. Patrick Soon-Shiong, chairman and CEO of ImmunityBio and NantKwest. “We believe this dual targeting is a key advantage that may lead to the stimulation of both T-cell-mediated and antibody-mediated immunity to SARS-CoV-2, which is an important differentiator from other vaccine candidates that only target the spike protein.”